OptimizeRx (OPRX) to Release Quarterly Earnings on Tuesday

OptimizeRx (NASDAQ:OPRX) is scheduled to issue its quarterly earnings data after the market closes on Tuesday, May 14th. Analysts expect the company to announce earnings of ($0.11) per share for the quarter. Persons that wish to listen to the company’s earnings conference call can do so using this link.

OptimizeRx (NASDAQ:OPRX) last issued its quarterly earnings data on Tuesday, April 16th. The company reported $0.11 earnings per share for the quarter. OptimizeRx had a negative net margin of 24.56% and a negative return on equity of 7.72%. The company had revenue of $28.37 million for the quarter. On average, analysts expect OptimizeRx to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

OptimizeRx Trading Down 0.9 %

NASDAQ:OPRX opened at $10.81 on Friday. The company has a market cap of $196.53 million, a PE ratio of -10.70 and a beta of 1.05. The company has a current ratio of 3.04, a quick ratio of 3.04 and a debt-to-equity ratio of 0.27. The company has a 50 day simple moving average of $11.62 and a two-hundred day simple moving average of $12.22. OptimizeRx has a 12 month low of $6.92 and a 12 month high of $16.65.

Analysts Set New Price Targets

Several analysts recently commented on OPRX shares. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $17.00 price objective on shares of OptimizeRx in a report on Monday, April 1st. JMP Securities restated a “market outperform” rating and set a $15.00 price target on shares of OptimizeRx in a research note on Tuesday, April 16th. Finally, Stifel Nicolaus reiterated a “buy” rating and issued a $13.00 price objective on shares of OptimizeRx in a research note on Monday, April 1st. One research analyst has rated the stock with a hold rating and six have assigned a buy rating to the stock. According to data from MarketBeat, OptimizeRx has an average rating of “Moderate Buy” and an average target price of $15.86.

OptimizeRx Company Profile

OptimizeRx Corporation, a digital health technology company, provides various solutions to life sciences organizations, healthcare providers (HCPs), and patients. Its products and applications include Evidence-Based Physician Engagement solution to assist HCPs in identifying patients who may be qualified for specific therapies, raise awareness of patient access pathways, and identify early indicators of non-adherence among patient populations; and Point of Care Banner messaging solution to deliver a variety of awareness and messaging within the clinical workflow.